Ipilumimab

DRUG2 trials

Conditions

Cutaneous Squamous Cell CancerCutaneous Squamous Cell CarcinomaCutaneous Squamous Cell Carcinoma (CSCC)Cutaneous Squamous Cell Carcinoma of the Head and NeckHigh Risk Melanoma

Phase 1

A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma

CompletedNCT01996202

Duke UniversityHigh Risk Melanoma

Start: 2013-11-30End: 2018-09-30Updated: 2019-07-05

Phase 2

Towards Cure Via Only Ultra-short ICB in CSCC

RecruitingNCT06823479

The Netherlands Cancer InstituteCutaneous Squamous Cell Cancer, Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma (CSCC) +1

Start: 2025-05-14End: 2029-02-28Target: 41Updated: 2025-05-29

Ipilumimab

Sponsors

Conditions

Phase 1

Phase 2